Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens. To determine the role of the invasion-related genes, invasive activities were evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens, when compared to that of normal human astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models. FGF13 was negatively regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.
INTRODUCTION
Glioblastoma has one of the poorest prognosis of intracranial tumors. Despite advances in basic and clinical studies, the outcomes of the patients remain poor, with the median survival time being 14.6 months. 1 The causes of glioblastoma poor prognoses include its typical aggressive invasiveness, high angiogenesis and proliferation. Recently, antiangiogenic treatments were used in clinical trials, however, no trials showed prolongation of overall survival (OS). 2, 3 Piao et al. 4 reported that anti-vascular endothelial growth factor therapy induced more invasive and treatment-resistant phenotypes. We have also shown that antiangiogenic therapy induced invasion in the orthotopic glioma models. 5, 6 Glioma cells often migrate along brain structures, including blood vessels and white matter tracts. 7 We have previously established two novel invasive glioma cell line models, J3T-1 and J3T-2, 8, 9 that mimicked the angiogenic and invasive phenotypes of human glioblastoma. 10 The J3T-1 model formed vascular rich tumor masses, and in adjacent normal brain tissues, the tumor cells clustered around the neovasculature. In contrast, the J3T-2 model formed tumor masses with the invasion of single cells into the normal brain parenchyma along white matter tracts. Previously, we reported that annexin A2, which was abundantly expressed in the J3T-1 model, was involved in angiogenesisdependent growth of glioma. 11 We further showed the presence of the newly identified invasion-related gene, fibroblast growth factor 13 (FGF13; also named fibroblast growth factor homologous factor 2 (FHF2)), a member of the FGF family, in the invasive J3T-2 glioma model. Recent studies showed that FGF13 was widely distributed in the developing brain, 12 and was involved in neural differentiation in early development of Xenopus 13 and in neural migration as a microtubule-stabilizing protein.
14 FGF13 had two alternative splicing forms: FGF13A that contained a nuclear localizing signal; and FGF13B that lacked the nuclear localizing signal. Nishimoto et al. 13 reported that FGF13 was increased by SoxD and was involved in the activation of the MEK5-ERK5 pathway in neuronal development. FGF13B regulated tubulin dynamics and was involved in neuronal motility.
14 Currently, many studies have shown that microtubules appear in glioma and that tumor cell migration and invasion required dynamic reorganization of the cytoskeleton, including actin and microtubules. 15, 16 As a result, microtubules have emerged as novel treatment targets to prevent tumor cell motility and invasion. 17 In this study, we showed that FGF13 was highly overexpressed in glioma and the silencing of FGF13 expression reduced glioma cell invasion in vitro and in vivo, thereby regulating microtubule dynamics. Moreover, bevacizumab-induced glioma invasion was impaired by knockdown of FGF13. RESULTS FGF13 was highly expressed in the invasive glioma model, in various human glioma cell lines and in human glioma stem cells To investigate the difference of invasive ability, the difference of gene expression profiles between J3T-1 and J3T-2 cells were analyzed using microarray data (Supplementary Figure 1A) . Gene Ontology enrichment analysis using these significantly regulated genes were performed (Tables 1 and 2 ). Gene Ontology enrichment analysis of J3T-2 revealed that upregulated genes in J3T-2 were mostly related to microtubule (P = 0.011) and cytoskeletal protein expression (P = 0.027). Among the genes in the microarray data involved in microtubule and cytoskeleton dynamics, FGF13 was overexpressed by 26.0-fold in J3T-2 cells compared to that of the J3T-1 cells. Then, we performed quantitative reverse transcription-PCR (qRT-PCR) assays to confirm the reliability of the results from microarray analyses and determined that the relative expression levels of FGF13 in J3T-2 cells were significantly elevated by 14.8-fold (Po 0.01) compared with that of the J3T-1 cells (Supplementary Figure 1B) .
Next, we screened FGF13 mRNA levels in several human glioma cells by using qRT-PCR. The U87ΔEGFR, U251 and LNZ308 cells showed higher expression of FGF13 than that of the normal human astrocyte cells, and were~14.7 times, 2.6 times and 4.1 times greater, respectively. Furthermore, the human glioblastomaderived cancer stem cells (MGG8 and MGG23) that showed a diffusely invasive phenotype, like the J3T-2 18 cells, also expressed higher FGF13 than that of the normal human astrocyte cells (41.7 times and 1.91 times, respectively, P o0.05).
The expression of FGF13 protein was dominant in the cytoplasm in glioma cell lines and human glioma specimens, and FGF13-positive glioma cells were located in the invasive edge Immunofluorescent staining of J3T-2 cells showed FGF13 (FGF13B) mainly localized in the cytoplasm ( Figure 1a) . Next, we also performed immunohistochemical staining of human specimens. In normal brain tissues, FGF13 was mainly expressed in the nucleus of neurons (Figure 1b) . However, in glioblastoma patient specimens, FGF13 protein was dominant in the cytoplasm (Figure 1c) . The relative expression level of FGF13 mRNA and protein in human glioblastoma specimens were significantly correlated (P = 0.016; Figure 1d ). Western blotting also showed FGF13B protein levels were higher than that of FGF13A in human glioblastoma specimens (Figure 1e ) and glioma cell lines (Figure 2b ). At the invasive edge, most tumor cells expressed FGF13 in the cytoplasm (Figure 1c , right panel), however, in the tumor core, the number of FGF13-positive cells varied in each patient ( Figure 1c, left panel) . The percentage of FGF13-positive tumor cells in the tumor core was 12.4%; however, the percentage was markedly increased in the invasive edge of the glioblastoma (44.6%) (P o 0.01; Figure 1f ). Data from the IVY Glioblastoma Atlas Project also showed that FGF13 was more expressed in the area of both the leading edge and infiltrating tumor than in the cellular tumor, perinecrotic zone, hyperplastic blood vessels and microvascular proliferations (glioblastoma.alleninstitute.org; Figure 1g ). Immunohistochemistry revealed that the microenvironment cells like endothelial cells and macrophages did not express FGF13 (Supplementary Figure 2) . We analyzed glioblastoma data from the Cancer Genome Atlas project and found that FGF13 was more expressed in proneural and neural subtypes than in classical and mesenchymal types (Figure 1h ). For the FGF13 expression based on glioma subtypes, data were analyzed using the Project Betastatis webpage (www.betastasis.com). Low-grade glioma also exhibited FGF13 (Supplementary Figure 3) .
Silencing of FGF13 reduced the in vitro migration and invasion activity To address the role of FGF13 in glioma, we examined the effect of FGF13 knockdown on cell migration and invasion. The small interfering RNA silencing of FGF13 expression reduced FGF13 mRNA expression in J3T-2 cells, and both FGF13 mRNA ( Figure 2a Figure 4C) .
Although the regulation of microtubules is usually involved in mitotic cell division in both normal and cancer cells, the watersoluble tetrazolium-1 cell viability assay showed FGF13 did not alter glioma cell viability (P = 0.359, 0.742, 0.899 and 0.37 in J3T-2, U87ΔEGFR, U251 and LNZ308 cells, respectively; Figure 2e ). Furthermore, FGF13-silenced cells did not indicate the increase of apoptosis (P = 0.82, 0.86, 0.70 and 0.62 in J3T-2, U87ΔEGFR, U251 and LNZ308 cells, respectively; Supplementary Figure 5 ). We also evaluated whether knockdown of FGF13 alter cell morphology. However, silencing of FGF13 did not significantly change cell morphology ( Supplementary Tables 1 and 2 ). Figure 3f ). The number of vessels in the tumor was also evaluated, however, there was no difference between the J3T-2 scramble shRNA and J3T-2 FGF13 shRNA samples (P = 0.51; Figures 3g and h ). The percentage survival of the J3T-2 FGF13 shRNA-treated samples was significantly greater than that of the J3T-2 scramble shRNA-treated samples (median survival = 59.5 versus 49 days; P = 0.0015; Figure 3i ).
We also investigated the role of FGF13 in glioma invasion using MGG8. Immunohistochemical examination of MGG8 showed these glioma cells spread from the injection site to the adjacent normal brain, like J3T-2 cells, and invaded along the corpus callosum. FGF13B regulated microtubule dynamics, and expression of FGF13 was negatively regulated by hypoxic conditions To clarify the functional mechanism of FGF13 in glioma invasion, we focused on the interactions between FGF13 and tubulin dynamics in glioma. Immunohistochemical staining showed that FGF13 was dominant in the cytoplasm of J3T-2 and colocalized with tubulin ( Figure 5a ). Next, we isolated the fraction of soluble tubulin (tyrosinated tubulin) and insoluble tubulin (acetylated tubulin; Ace-tubulin) from A172 cells transfected with the FGF13B plasmid or untransfected cell and treated with dimethyl sulfoxide or nocodazole, a microtubule destabilizer. The tyrosinated tubulin or Ace-tubulin are markers for dynamic or stable microtubules, respectively. Western blotting showed Ace-tubulin in normal A172 was decreased after treatment with nocodazole. However, FGF13B restored the level of Ace-tubulin in A172 cells treated with nocodazole ( Figure 5b ). These results showed that FGF13B colocalized with tubulin and could stabilize the microtubule structures. We assessed the role of hypoxic conditions as a mechanism of affecting FGF13 expression. Silencing of FGF13 altered bevacizumab-induced glioma invasion Recently, bevacizumab has been used for glioblastoma treatment and shows benefits in progression-free survival. However, bevacizumab was reported to induce invasion and this may lead to failures of prolongation of OS. We therefore investigated whether FGF13 also regulated bevacizumab-induced glioma invasion.
First, we evaluated the expression of FGF13 after bevacizumab treatment in human glioma cell lines (Figure 6a Figures 8A and B) . We analyzed the FGF13 mRNA expression in five patients who had both pre-and post-bevacizumab specimens, using a previously published microarray data. 19 No changes in FGF13 expression occurred after bevacizumab resistance (Figures 6c; P = 0.7278). Immunohistochemistry of FGF13 in our cohort also confirmed these data (Supplementary Figure 8E) .
Next, we evaluated the role of FGF13 on bevacizumab-induced glioma invasion in vitro and in vivo using our previously reported bevacizumab-induced glioma invasion model. 6 In vitro, doublechamber assays showed that bevacizumab treatment significantly induced glioma cell invasion, however, silencing of FGF13 decreased its invasion ability in both U87ΔEGFR and U251 cells Figures 8C and D) . We generated U87ΔEGFR cells expressing FGF13 shRNA or scramble shRNA ( Figure 6d ) and transplanted each cell type in vivo into the brain of athymic mice. These mice were treated with either phosphate-buffered saline or bevacizumab. Mice in the phosphate-buffered saline-treated group showed tumor masses with well-defined borders (Figure 6e ). However, in the bevacizumab-treated group, tumor cell invasion into surrounding normal tissues was induced and the tumor surface became irregular. We evaluated the depth of tumor invasion from the border of the tumor mass to the invaded cells. In U87ΔEGFR expressing scramble shRNA treated with bevacizumab, the mean depth of tumor invasion was 222.7 ± 34.9 μm. However, the depth of tumor invasion in the U87ΔEGFR expressing FGF13 shRNA samples treated with bevacizumab was remarkably decreased (mean, 111.9 ± 16.8 μm, P o0.05; Figures 6e and f; Supplementary Figures 8F and G) . These results demonstrated that FGF13 was also involved in bevacizumab-induced glioma invasion.
DISCUSSION
In the present study, our findings suggested that FGF13 regulated microtubule dynamics and was involved in glioma invasion in vitro and in vivo. FGF13-related invasion was observed in both glioma non-stem cells and glioma stem cells. In addition, knockdown of FGF13 reduced bevacizumab-induced glioma invasion.
FGFs are widely distributed in both normal cells and cancer cells, and have a wide range of biological activities, including cell proliferation, differentiation and migration. In glioblastoma, several FGFs are known to be involved in pathogenesis or malignancy. 20 Generally, FGFs act through their specific signals by binding to their receptors. However, FGF13 (FHF2) and other FHF family members (FGF11, FGF12 and FGF14) lack a N-terminal signal peptide for secretion and function and therefore, FGF13 cannot be secreted or bind to cell surface FGF receptors. FGF13 is involved in the intracellular regulatory mechanism. Wu et al. 14 reported that FGF13 regulated tubulin dynamics and invasive activity in neurons. Recently, the role of FGF13 in several cancers was also investigated. Okada et al. investigated the overexpression of FGF13 in HeLa cisR cells, which caused greater resistance to cisplatin. Cervical cancer patients with higher FGF13-positive cells showed poor prognosis after chemoradiotherapy. 21 Yu et al.
22
reported high expression of FGF13 in the cytoplasm, which was associated with a shortened time to biochemical recurrence after surgery in prostate cancer. Less has been reported on the role of FGF13 in glioma. Saito et al. 23 reported that FGF13 was highly expressed in γ-secretase inhibitor non-responder group when compared with responder group. Other studies reported the knockdown of SOX2 changed FGF13 expression in glioblastoma. 24, 25 However, the functional role of FGF13 in glioma was not fully elucidated. We found that cytoplasmic FGF13 regulated tubulin dynamics and glioma invasion. Recently, a number of studies found the cytoskeleton had an important role in glioma invasion. 15, 26 The cytoskeleton consists of three major classes of structural components, including the microtubules (tubulin), actin filaments (actin) and intermediate filaments. In particular, microtubules and actin filaments are important in cell motility, and the crosstalk between these proteins is also important in cell migration. 27 Both protein types are found in the cytoplasm but can be distributed in different parts of the cytoplasm. Some tubulin-associated proteins have been reported to regulate glioma invasion. Dráberová et al. 28 showed that silencing of the microtubules severing ATPase spastin in human glioblastoma cells inhibited cell motility. Song et al. 29 demonstrated that silencing of the microtubule-destabilizing phosphoprotein, stathmin, inhibited invasion and increased chemosensitivity of cancer stem cells. Also, many tubulintargeted therapies have been reported and showed clinical benefit in glioma, including the microtubule-stabilizing tubulinbinding agent patupilone, 30 valproic acid 31 and tumor-treating fields. 32 We first reported that FGF13 regulated glioma invasion by stabilizing microtubules in the leading edge of the tumor, and that silencing of FGF13 in vivo significantly prolonged the survival time of xenograft models. However, as previously reported, the survival benefit achieved by inhibiting invasion has little impact. 26 Three possible reasons could explain the survival benefit derived from FGF13 deletion. First, it is possible that inhibition of glioma invasion may prolong xenograft survival. Whether inhibition of glioma invasion could prolong survival is not well-known. Nagai et al. 33 reported that regulation of invasion did not change the survival time. In contrast, Hayashi et al. 26 showed that inhibition of glioma invasion could significantly prolong survival time, but the number of survival benefit days was within 15% of the OS time. Our xenograft models showed a survival benefit; however, the number of survival benefit days were 17.6%, 9.8% and 14.7% in J3T-2, MGG8 and MGG23 cells, respectively. These percentage are agreement with those of Hayashi et al. Second, it is also possible that other cellular processes related to microtubules were dysfunctional and this led to tumor cell death. Microtubules are highly dynamic structures that have important roles in cells, including vesicular transport processes other than during mitosis or migration. Third, it is possible that FGF13 interacts with voltagegated sodium channel proteins (Na v s) in neurons 34 and may also interact with Na v s in some cancers. 21, 22 Na v s is essential for glioma formation, so it may change the survival time in xenograft models.
Randomized, placebo-controlled phase III trials of AVAglio and RTOG-0825 in newly diagnosed glioblastoma, with the addition of bevacizumab to radiotherapy plus temozolomide, could not prolong OS. 2, 3 One reason for this result could be that antivascular endothelial growth factor therapy induced a phenotypic shift 35 toward a more invasive, aggressive and treatment-resistant phenotype. Some signaling pathways such as MET, 36 PI3K or Wnt 37 are known to be activated to promote invasion after bevacizumab treatment. We showed that FGF13 was also involved in bevacizumab-induced glioma invasion in animal model. We thought FGF13 expression might be increased to induce invasion Microarray data for human specimens also showed same result, although we did not show FGF13A and FGF13B separately in these data. It is possible that FGF13B, which is mainly expressed in cytoplasm, is only increased in human specimens. These results may suggest that FGF13 is an innate factor, which drives glioma invasion, and glioma cells remain dependent on FGF13 for their invasion after bevacizumab treatment. Delay et al. 19 reported that patients in their secondary data set with high expression of FGF13 before bevacizumab treatment showed shorter OS after bevacizumab treatment. Combination of some drugs like cilengitide 6 or altiratinib 38 with bevacizumab was previously reported to suppress bevacizumab-induced glioma invasion, therefore, FGF13 also could be a novel target of bevacizumab treatment.
In conclusion, our research first reported that FGF13 was mainly expressed in the cytoplasm of glioma cells and in the invasive edges of tumor specimens, and was therefore related to glioma invasion. Furthermore, FGF13 was also related to bevacizumabinduced glioma invasion. Our results suggested that FGF13 could be a promising new target to treat and prevent glioma invasion.
MATERIALS AND METHODS

Culture of established cell lines and glioma stem cells
As previously reported, the canine glioma cell lines, J3T-1 and J3T-2, were derived from the same parental glioma cells (J3T) and were characterized. 8, 39 The J3T cell line was a gift from Dr Michael E Berens at Barrow Neurological Institute. 40 The A172 and Gli36Δ5 41 cells were obtained from Dr EA Chiocca at Massachusetts General Hospital, Boston, MA, USA. The U87ΔEGFR and U251 cells were obtained from Dr Balveen Kaur at Ohio State University, Columbus, OH, USA. The human glioblastoma-derived cancer stem cell line, MGG8 and MGG23 cells were provided by Dr Hiroaki Wakimoto at Massachusetts General Hospital. Normal human astrocyte cells were purchased from Takara Bio Inc. (Shiga, Japan). J3T-1, J3T-2, U87ΔEGFR, U251, LNZ308, A172 and Gli36Δ5 were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U of penicillin and 0.1 mg/ml of streptomycin. The human glioblastoma-derived cancer stem cell line, MGG8 and MGG23 cells were cultured as previously described. 18, 42 For hypoxic conditions, the cells were cultured with 1% O 2 or in medium containing 100 μM deferoxamine mesylate (Sigma-Aldrich, St Louis, MO, USA). U87ΔEGFR, U251 and A172 were authenticated by Promega (Madison, WI, USA) via short tandem repeat profiling in December 2016. Mycoplasma is negative in all cells.
Human glioblastoma specimens
Twenty-five human glioblastoma specimens were randomly selected from 80 glioblastoma patients treated at the Okayama University Hospital between 2006 and 2016. The study (1603-070) was approved by the ethical committee of the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Informed consent was obtained from all patients included in the study. For pathological analyses, we defined the tumor core and the invasion edge as corresponding to the cellular tumor and infiltrating tumor as defined in the IVY Glioblastoma Atlas Project (http://glioblastoma.alleninstitute.org/). Among 25 specimens, all included the region of tumor core, but only 8 specimens had the region of invasion edge. We also evaluated FGF13 mRNA of 12 corresponding tumors from frozen samples that were available for qRT-PCR.
Microarray assays
Total RNA from J3T-1 and J3T-2 cells were isolated using the RNeasy kit (Qiagen, Santa Clarita, CA, USA) and were analyzed using a GeneChip Canine Genome 2.0 Array (Affymetrix, Santa Clara, CA, USA). The microarray analyses were performed by Takara Bio Inc. Briefly, biotinylated cRNA was synthesized by the GeneChip 3'IVT Express Kit (Affymetrix) from 250 ng total RNA, according to the manufacturer's instructions. Biotinylated cRNA yields were checked with the NanoDrop ND-2000 Spectrophotometer (Thermo Fisher Scientific, Scotts Valley, CA, USA). Following fragmentation, 10 μg of cRNA were hybridized for 16 h at 45°C on the GeneChip Canine Genome 2.0 array. Arrays were washed and stained using the GeneChip Fluidics Station 450 instrument (Affymetrix). Arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix). Single-array analyses were calculated using the Microarray Suite version 5.0 (MAS5.0) with Affymetrix default settings and global scaling as the normalization methods. The trimmed mean target intensity of each array was arbitrarily set to 500. Genes with absolute value of the fold change at least 2.0 and P-value o0.05 were considered to be significantly regulated. Gene Ontology enrichment analysis was performed using the functional annotation tool Database for Annotation Visualization and Integrated Discovery (DAVID) 6.8 (http://david.abcc.ncifcrf.gov/home.jsp), and significant Gene Ontology terms were identified at Po0.05. 43 All data are deposited in the Gene Expression Omnibus (accession number GSE88740).
RNA isolation, cDNA synthesis and qRT-PCR We isolated total RNA from the cell lines or human glioblastoma specimens, and synthesized cDNA with the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). The qRT-PCR reactions were then performed and detected using the StepOnePlus system (Life Technologies, Carlsbad, CA, USA).
As an internal control, we used β-actin (ACTB) mRNA. Primers were designed with the Primer3 Plus software (http://www.bioinformatics.nl/cgibin/primer3plus/primer3plus.cgi) and were purchased from Invitrogen. The primer sequences used were as follows:
Canine FGF13 primers: forward, 5′-GTAGCCAGTGAGGGCAAGAC-3′; reverse, 5′-AGTCTGCTGCACAAGCTCAA-3′.
Canine ACTB primers: forward, 5′-TGCGTGACATCAAGGAGAAG-3′; reverse, 5′-AGGAAGGAAGGCTGGAAGAG-3′.
Human FGF13 primers: forward, 5′-ACAAGCCTGCAGCTCATTTT-3′; reverse, 5′-CATTGTGGCTCATGGATTTG-3′.
Human CA9 primers: forward, 5′-TATCTGCACTCCTGCCCTCT-3′; reverse 5′-ACAGGACAGTTACCGGCTC-3′. Human ACTB primers: forward, 5′-GGACTTCGAGCAAGAGATGG-3′; reverse, 5′-AGCACTGTGTTGGCGTACAG-3′.
Plasmids, RNA interference and lentiviruses
The human FGF13B plasmids were purchased from GeneCopoeia (Rockville, MD, USA). We added a nuclear export signal to the N terminus of FGF13B to avoid the nuclear import of overexpressed FGF13B, as previously reported.
14 Small interfering RNA against canine or human FGF13 and negative control RNA were obtained from Thermo Fisher Scientific and transfected with Lipofectamine 3000. The lentivirus encoding scramble shRNA and shRNA against canine or human FGF13 were prepared using the pLKO.1, psPAX2 and pMD2.G plasmids (Addgene, Cambridge, CA, USA), 293FT cells and FuGENE 6 Transfection Reagent (Promega) according to the manufacturer's recommendations.
Migration and invasion assay
For scratch assays, we seeded each cell at 70-90% confluency. One day before the scratch, we changed the medium into DMEM with 0.1% FBS for starvation. Then, the cells were scratched, cultured for 24 h and observed. The transwell and invasion assays were performed using a ThinCert Tissue Culture Insert (Greiner Bio-One, Frickenhausen, Germany) and BioCoat Matrigel invasion chamber (BD Bioscience, Franklin Lakes, NJ, USA) according to the manufacture's instructions, respectively. In brief, we seeded 1 × 10 5 cells in DMEM with 0.1% FBS in the upper chamber and filled with DMEM with 10% FBS in lower chamber. After 24 h incubation, the filters of inserts were fixed with methanol and stained with Giemsa solution. We calculated the number of invading cells on the lower surface of the filter.
Western blot analysis
We prepared cell lysates and proteins using RIPA buffer and phenylmethylsulfonyl fluoride (Cell Signaling Technology, Danvers, MA, USA), and isolated tubulin as previously described.
14 And then, we performed western blotting as previously described. 44 After blocking, the membranes were incubated overnight with primary antibodies (anti-FGF13, Sigma-Aldrich, 1:300 dilution; anti-β-actin, SigmaAldrich, 1:5000 dilution; anti-acetylated-tubulin, Abcam, Cambridge, UK, 1:1000; anti-α-tubulin, Cell Signaling Technology, 1:1000) at 4°C. The secondary antibodies used were horseradish peroxidase-conjugated antimouse IgG and HRP-conjugated anti-rabbit IgG (Cell Signaling Technology, 1:5000). HRP signals were analyzed by the VersaDoc molecular imaging system (Bio-Rad, Hercules, CA, USA).
Immunofluorescence and immunohistochemistry
Immunofluorescent and immunohistochemistry analyses were carried out as previously described. 6, 11 Following antibodies were used for immunofluorescent: anti-FGF13, 1:100; anti-β-tubulin, Sigma-Aldrich, 1:1000; antivimentin, DakoCytomation, Carpentaria, CA, USA, 1:100; anti-ki67, Leica Biosystems, Wetzlar, Germany, 1:150; and Alexa Fluor 488-or Alexa Fluor 594-conjugated antibodies, Life Technologies, 1:250. F-actin was stained using the CytoPainter F-actin Labeling Kit (Abcam) according to the manufacturer's protocol. Immunofluorescent images were obtained with a confocal laser microscope (LSM 780; Zeiss, Jena, Germany).
The following antibodies were used for immunohistochemistry: anti-FGF13, 1:100; anti-HLA, Abcam, 1:100; anti-CD31, Abcam, 1:50; anti-Iba-1, Abcam, 1:250; and anti-goat IgG-HRP, Santa Cruz, 1:200. The Dako Envision + System-HRP Kit was then used in accordance with the manufacturer's protocol (DakoCytomation) and the sections were counterstained with hematoxylin. Immunohistochemistry samples were observed with the BZ-8100 microscope (Keyence, Osaka, Japan).
Apoptosis assay
Apoptotic tumor cells were detected using an In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) according to the manufacturer's protocol.
Water-soluble tetrazolium-1 assay For analyses of glioma cell proliferation, the water-soluble tetrazolium-1 assay was performed according to the manufacturer's protocol (Roche). In vivo experiments
All experimental animals were housed and handled in accordance with the guidelines of the Okayama University Animal Research Committee, and all of the procedures and animal protocols were approved by the Committee on the Ethics of Animal Experimentation at Okayama University. Six-weekold female athymic or severe combined immunodeficiency mice were purchased from Clea Japan Inc. (Tokyo, Japan) or Charles River Laboratories Japan (Yokohama, Japan), respectively. The J3T-2, MGG8, MGG23 or U87ΔEGFR cells (2 × 10 5 cells) expressing scramble shRNA or shRNA against canine or human FGF13 were stereotaxically injected into the right frontal lobe (3 mm lateral to the midline, 1 mm anterior to the coronal suture and 3 mm depth from the dura), using a stereotactic frame (Narishige, Tokyo, Japan) and Hamilton syringe (Hamilton, Reno, NV, USA) as previously described. 6 Mice bearing U87ΔEGFR cells were randomized into control or treatment groups. We administered phosphate-buffered saline or bevacizumab (6 mg/kg) intraperitoneally three times per week, which we started on day 5 after implantation. Bevacizumab was provided by Chugai Pharmaceutical Co. (Tokyo, Japan). Group allocation was not blinded.
Statistical analyses
Statistical analyses were performed using SPSS statistical software (version 20; SPSS, Chicago, IL, USA). The results of percentages of FGF13-positive cells, the MIB-1-labeling indices, vessel density, percentages of TUNELpositive cells and the relative mRNA and protein expression were analyzed using Student's t-tests. The results of relative mRNA expression, migration assays, water-soluble tetrazolium-1 assays, percentages of TUNEL-positive cells and invasion assays were analyzed using the two-way analysis of variance test. Kaplan-Meier curves were compared using the log-rank test. P-values o0.05 were considered statistically significant. For statistical analyses, experimental replicates from at least three samples were compiled for each experiment, unless otherwise stated in the figure legend. The data represent the mean ± s.e.m.
